Integrated Symposia
For the full programme of the Integrated Symposia please click here
12:15 – 13:15
AstraZeneca
Protecting vulnerable populations from COVID-19
12:15 – 13:15
Abbott
The lab of the future: how COVID-19 taught us the value of a transcendent laboratory service
12:15 – 13:15
Copan Italia S.p.a
Sample self-collection, a lesson gained during the COVID pandemic
12:15 – 13:15
MeMed
Leveraging the host response to acute infection to create new diagnostic and prognostic tools
12:15 – 13:15
GSK-AMR
A spotlight on antibiotic resistance in community settings: uncomplicated urinary tract infections
13:30 – 15:30
Pfizer
Building on a strong foundation to address a new era to help protect against pneumococcal disease
13:30 – 15:30
GSK
Role of monoclonal antibodies (mAbs) in the evolution of early treatment in COVID-19
13:30 – 15:30
Janssen Pharmaceuticals
COVID-19 vaccines: lessons learnt and prospects in 2022
13:30 – 15:30
Moderna
mRNA science: a paradigm shift to address unmet medical needs
16:15 – 18:15
Pfizer
MDR Gram-negative infections in a pandemic world: contemporary treatment options
16:15 – 18:15
MSD
Best of both worlds: maximising serotype coverage and quality of immune responses for pneumococcal disease prevention
16:15 – 18:15
Bruker Daltonics GmbH & Co KG
Changing microbiology: focus to critical infectious diseases by state-of-art technologies
16:15 – 18:15
SD Biosensor
The usefulness of various Point-of-Care tests against evolving COVID-19
16:15 – 18:15
Menarini Group
Expected impact on clinical outcomes of early identification and early management of MDR Gram-negative infections
08:30 – 10:30
QIAGEN
After the COVID-19 tide: exploring novel approaches in infectious diseases diagnostics from syndromic to immune testing
08:30 – 10:30
MSD
Conquer the case: integrating microbiological testing and the immune status of the host into clinical decision making
08:30 – 10:30
Seegene Inc.
Facing a ‘new normal’: co-existence of SARS-CoV-2 and respiratory virus
08:30 – 10:30
GSK-AMR
A Moment to Reset: harnessing learnings to tackle antimicrobial resistance in the community
08:30 – 10:30
Mundipharma
Spotlight on antifungals: are we well equipped for treating invasive fungal disease?
12:15 – 13:15
AstraZeneca
Staying ahead of the virus: evolving preventative strategies to manage COVID-19 variants
12:15 – 13:15
QuantaMatrix Inc.
Rapid AST on positive blood cultures: new standards in rapid susceptibility testing?
12:15 – 13:15
Tillotts Pharma
Control disease immediately: think C. difficle infection, think COVID!
12:15 – 13:15
Insmed Ireland Ltd
Time to rethink NTM: understanding your at-risk MAC-PD patients and optimising their outcomes
12:15 – 13:15
InfectoPharm Arzneimittel und Consilium GmbH
Intravenous fosfomycin: comprehensive new data evaluation for this WHO essential antibiotic for treatment of adult and pediatric patients with severe infections
13:30 – 15:30
Pfizer
Future-proofing mould disease diagnosis and treatment: the post-pandemic era
13:30 – 15:30
MSD
COVID-19 today: outpatient treatment options and considerations
13:30 – 15:30
Gilead Sciences Europe Ltd
Optimizing treatment of invasive fungal infections in critically ill patients
13:30 – 15:30
Thermo Fisher Scientific
Moving insights into action: how innovative rapid diagnostics impact treatment decisions
13:30 – 15:30
Oxfrod Nanopore Technologies
Evolution of rapid metagenomics for infectious disease applications
16:15 – 18:15
Pfizer
New data, fresh perspectives: an update on CAP and cSSTI
16:15 – 18:15
F2G Ltd
Reviewing 20 years of managing invasive mould infections: lessons learned and remaining challenges
16:15 – 18:15
Menarini Group
In light of the COVID-19 pandemic: how can new antibiotics help reduce the pressure on hospitals and facilitate early discharge?
16:15 – 18:15
Hologic
Innovative and scalable molecular solutions for infectious disease testing
16:15 – 18:15
Sanofi Pasteur
RSV burden: the need for all infant protection
08:30 – 10:30
Pfizer
The science of mRNA COVID-19 vaccines: paving the way for a new prevention paradigm
08:30 - 10:30
Janssen Pharmaceuticals
RSV in adults: the hidden enemy?
08:30 - 10:30
Roche
Ongoing challenges in pandemic management
12:15 – 13:15
T2 Biosystems
Rapid culture-independent diagnostics charting a new course for sepsis management and antimicrobial stewardship
12:15 – 13:15
Siemens Healthineers
Testing for respiratory viruses: a dynamic field in an evolving environment
12:15 – 13:15
Medicago Inc.
The transition from emergency to routine SARS-CoV-2 vaccines: what data do we have and what data do we need?
12:15 – 13:15
Seegene Inc.
How multiplexed molecular testing for infectious disease is evolving
12:15 – 13:15
bioMérieux
Faster ID and AST revolution: how to improve antibiotic use in critically ill
13:30 – 15:30
Pfizer
Fighting COVID-19: how healthcare advances are tipping the scale in humanity's favour
13:30 – 15:30
Gilead Sciences Europe Ltd
The calm after the storm? Antivirals for hospitalised patients with COVID-19 in the post vaccination era
13:30 – 15:30
Shionogi
Treating Gram-negative infections caused by pathogens with limited treatment options: unanswered questions and emerging evidence
13:30 – 15:30
Sanofi Pasteur
Influenza vaccination: protection beyond flu
13:30 – 15:30
Cepheid
Innovating patient care with PCR diagnostics: the fast, the accurate, and the easy
13:30 – 15:30
Abbott
Transitioning to endemic COVID-19 testing: evidence-based assessment on current and future rapid antigen test detection
16:15 – 18:15
Beckman Coulter
Antimicrobial resistance and detection: a continued critical issue
16:15 – 18:15
Sanofi Pasteur
What matters in the fight against COVID-19: how to keep high levels of protection in a multivariant environment?
16:15 – 18:15
Illumina Cambridge
Moving next-generation sequencing to clinical microbiology laboratories: the future is now!
16:15 – 18:15
Shionogi
The current and emerging antiviral landscape for SARS-CoV-2
08:30 – 10:30
RMEI Medical Education
Confronting CMV in the transplant population: applying the guidelines amid new therapeutic options
08:30 – 10:30
GSK (Vaccines)
How can vaccinology impact healthy ageing?
08:30 – 10:30
DiaSorin S.p.A.
Improving patient health care in COVID-19 era
08:30 – 10:30
Novartis
Therapeutic innovations in COVID-19: anti-spike biologics with pan-variant activity
12:15 – 13:15
Medscape LLC
Cytomegalovirus prevention: current challenges and future prospects in CMV
